Aust Ctr for Blood Diseases

    Research areas

  • Cytokine, Gene Transcription, Phosphatidyl Inositol 3-Kinase, Leukaemia, Apoptosis, Signalling, Kinase, Phosphorylation


Dr. Mark Guthridge completed his Ph.D studies at Monash University after which he took up a postdoctoral position at New York University Medical Centre as a Darland Research Fellow. He returned to the Institute of Medical and Veterinary Science, Adelaide Australia in 1998 and was awarded a Peter Nelson Leukaemia Research Fellowship to examine molecular approaches for the therapeutic targeting of acute myeloid leukemic (AML) cells. In 2011 Dr. Guthridge moved his laboratory to the Division of Blood Cancers at the Australian Centre for Blood Diseases (ACBD) located on the Alfred Medical Research and Education Precinct (AMREP) in Melbourne.

Since 2000, Dr. Guthridge's lab has received continual funding from International (NIH, AICR), National (NHandMRC, LFA) and State agencies (Cancer Council of SA). His work has been published in top-tier journals including Cell, Molecular Cell, Cell Stem Cell and EMBO J as well as leading specialist cancer/hemopoietic journals such as Blood, Leukemia and Cancer Research. Dr. Guthridge regularly serves of NHandMRC GRPs and is co-convenor of the New Directions in Leukaemia Research (NDLR) conference held biennially on the Sunshine Coast, QLD.

Dr. Guthridge's research focuses on the mechanisms by which cancer cells co-opt and coerce intracellular signalling pathways to promote deregulated cell survival, proliferation and growth. Through the molecular analysis of intracellular signalling pathways, Dr. Guthridge's laboratory seeks to identify new therapeutic targets in diseases such as leukaemia.


Dr. Guthridge consulted for the Commonwealth Serum Laboratories (CSL) between 2004-2009.

ID: 811072